You are here

TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N43CA130021
Agency Tracking Number: N43CA130021
Amount: $249,672.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
P O Box 3131
BOULDER, CO 80307-3131
United States
DUNS: 963360719
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 GIJSBERTUS PRONK
 (303) 921-6680
 PRONKGJ@YAHOO.COM
Business Contact
 GIJSBERTUS PRONK
Phone: (303) 921-6680
Email: PRONKGJ@YAHOO.COM
Research Institution
 Stub
Abstract

The long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HNC. Head and Neck Cancers remain hard to control even with surgery and high doses of radiation, both of which have devastating side effects. New drugs that enhance standard therapies by reducing resistance and preventing re-population after these treatments have the potential to improve clinical practices. Successful completion of this project will yield a drug candidate that can be carried into PD/ADME/toxicology analysis towards IND filing. PUBLIC HEALTH RELEVANCE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government